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From chemistry to biology database curationThere is a wealth of valuable chemical information in
publicly available databases for use by scientists under-
taking drug discovery. However finite curation re-
source, limitations of chemical structure software
and differences in individual database applications
mean that exact chemical structure equivalence be-
tween databases is unlikely to ever be a reality. The
ability to identify compound equivalence has been
made significantly easier by the use of the International
Chemical Identifier (InChI), a non-proprietary line-no-
tation for describing a chemical structure. More im-
portantly, advances in methods to identify compounds
that are the same at various levels of similarity, such as
those containing the same parent component or having
the same connectivity, are now enabling related com-
pounds to be linked between databases where the
structure matches are not exact.
Introduction
Because of the pressures in the pharmaceutical industry of
increasing drug development costs, greater requirements for
safer medicines and desire for prescribers to show value for
money, over the past 5–10 years the industry has changed*Corresponding author: A. Hersey (ahersey@ebi.ac.uk)
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such that increasingly early drug discovery is being undertaken
by SMEs (small to medium sized enterprises) and in academic
groups. These groups do not have the large chemical and
biological databases of the large Pharma companies and so
are more reliant on the data available in public domain data-
bases. The availability of open access databases on the Internet
has greatly increased over the past 5 years. This itself brings
advantages of chemical structure diversity but also disadvan-
tages of lack of standardisation, particularly in chemical struc-
tures, as organisations have evolved their own business rules
for standardising chemical structures and have limited
resources for curation activities. This paper will outline some
of the valuable resources available to drug discovery research-
ers, highlight some of the issues around curation and standar-
disation and discuss some of the methods and tools available to
overcome some of these issues.
Open and public domain databases
The available public domain databases that are specifically
aimed at drug discovery scientists all have their own specialist
content and, in general, this is complementary. For example,
vendor information, patented compounds, data on marketed
drugs, as well as bioactivity data for both efficacy and liabilityoi.org/10.1016/j.ddtec.2015.01.005 17
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Table 1. Examples of some publicly available databases containing chemical information including a description of their content
and the number of compounds they contain
Database Content Size (no. of
compounds)
URL Reference
Bioactivity data
ChEMBL Bioactivity data from the medicinal chemistry literature 1 360 000 https://www.ebi.ac.uk/chembldb [25]
PubChem Biological screening results on small molecules 49 000 000 https://pubchem.ncbi.nlm.nih.gov/ [14]
Patents
IBM Chemicals from full text patents 2 500 000 http://www-935.ibm.com/services/us/gbs/bao/siip/
SureChEMBL Chemicals from full text patents 12 400 000 https://www.surechembl.org
Drugs
DRUGBANK Drug data and drug target information 7700 http://www.drugbank.ca [26]
FDA/USP SRS Substances present in FDA regulated products 34 000 http://fdasis.nlm.nih.gov/srs/srs.jsp
Availability
ZINC Commercially available compounds 22 700 000 http://zinc.docking.org [27]
emolecules Commercially available compounds 5 900 000 http://www.emolecules.com
Other
ChEBI Database and ontology of Chemical Entities of
Biological Interest
27 000 https://www.ebi.ac.uk/chebi/ [20]
PDB Data on biological macromolecular structures 16 000 https://www.ebi.ac.uk/pdbe/ [28]
Note: All numbers from Apr 2014.targets and crystal structures of small molecules bound to
protein targets, can all be found in public databases. The
number of compounds ranges from the comparatively small
manually curated sets, such as ChEBI, to large patent data-
bases, such as SureChEMBL, where the data is extracted from
patents using ‘name to structure’ and ‘image to structure’
software and for which manual curation would be an prohib-
itively expensive task. Table 1 summarises some of these
databases for which the chemical structures, identifiers and
in many cases additional data can be freely downloaded.
As well as their own primary content, some databases also
take depositions from other databases, or directly from
depositors. For example: PubChem includes data from
ChEMBL and ChEBI, alongside an extensive set of user
depositions; ChEMBL includes some data from PubChem,
and ZINC contains data from ChEMBL. Similarly, the Open
PHACTS drug discovery platform [1] includes data from
ChEBI, ChEMBL and DrugBank and tracking data provenance
under these circumstances is challenging. ChemSpider [2] is a
chemical structure database that currently integrates data on
about 30 million chemicals from more than 470 other data-
bases of varying content. The difference between ChemSpider
and the aforementioned databases, is that while users can
search for compounds online and get links to data in the
originating databases it isn’t possible to download the Chem-
Spider compounds as a complete dataset. Given the trend for
aggregating database content, it is particularly important that
database providers supply attributions to the data so that the
provenance can be determined.
Much has been written about the quality of data, both
chemical and biological, in public databases and the impact18 www.drugdiscoverytoday.comof incorrect structures on modelling [3–5]. Data quality will
undoubtedly be varied for different databases and it would be
unreasonable to expect to see the same degree of curation on
a database of 10 million compounds and one with only a few
thousand. What is certain is that all data providers will curate
compounds to the best of their abilities and as far as their
budget allows. However, even with resource and time to do it,
there are several factors that will lead to the same compound
appearing to have different structures in different databases.
Sources of structure differences
One difficulty encountered when trying to curate chemical
structures is that often there is no definitive source for a
structure. Until recently, marketed drugs were a key example
of this and although attempts are now being made to create a
definitive database of structures [6] it seems that more cura-
tion is needed [3].
In scientific publications, compound structures are often
drawn in a form that has relevance to the context of the
paper. For example, in a docking paper an acidic or basic
molecule might be drawn as a negatively or positively
charged molecule as this is the relevant form for binding
to the protein. Other papers might report bioactivity data and
display the parent form of the molecule even though the
dosed substance was its salt. Using trivial names such as USAN
(United States Adopted Name) and INN (International Non-
proprietary Name) for drugs to try and identify their struc-
tures is also fraught with difficulties. An INN is, in most cases,
filed for a parent structure whilst since 2004, different USANs
need to be filed for both the parent and the salt structures.
Prior to 2004, only the marketed form (often a salt or ester)
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Molecule Representation 
(a) (b)
(c)
Source InChIKey
USAN GCWZHWKRAHFLED-NATOKKMCSA-N 
ChEMBL,  DailyMed GJJFMKBJSRMPLA-UHFFFAOYSA-N 
DrugBank, Kegg GJJFMKBJSRMPLA-HIFRSBDPSA-N 
Molecule Representation Source InChIKey
PubChem
(CID41203) 
BSJGASK RWFKGM V-
UHFFFAOYSA-L
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Figure 1. Examples of different structure representations and the effect of these representations on the InChIKey. (a) Examples of database structure
representations for Milnacipran. (b) Examples of database structure representations for Cisplatin. (c) Examples of tautomers with matching and non-
matching Standard InChIs.would require an USAN. Taking Sildenafil Citrate as an ex-
ample, the respective USAN is ‘Sildenafil Citrate’ whereas
there is no INN filed for this salt. However, an INN has been
recommended for the parent of this salt and that is ‘Sildena-
fil’. While a clear mapping between a structure and a syno-
nym is possible when examining the original source of the
synonym, confusion may arise when examining a source of
compiled synonyms, such as the USP Dictionary [7]. In this
dictionary, for USANs adopted prior to 2004, the INN is often
recorded against the USAN structure, which in most cases is a
salt. Hence for this example, not only the USAN, but also the
INN Sildenafil, will be recorded against the structure of
Sildenafil Citrate. This illustrates how the use of these trivial
names can lead to confusion and mismatches with different
structures being given the same name.
Currently, most chemical structures in the scientific liter-
ature appear as images and not in a structure readable format.
This means that the process of extracting the chemical struc-
tures and loading them into a database entails redrawing the
structure from the image in the paper, or using image to
structure software, or a combination of both. Inevitably, this
will introduce structure errors, which won’t be prevented
unless journal editors insist on structure files being submitted
for chemical structures [8].Software limitations
Almost all public databases are using the v2000 molfiles [9] as
the preferred way of storing chemical structures and these
have some limitations in their ability to represent certain
types of compounds. Firstly, they cannot represent com-
pounds that have two stereogenic centres and are a mixture
of two enantiomers but do not contain any of the diaster-
eoisomers. The drug Milnacipran is a typical example of this
as it is a mixture of the 1R, 2S and 1S, 2R enantiomers. But
how best to represent this? It can be drawn on paper as a
mixture (Fig. 1a) and this is how it appears in the American
Medical Association’s USAN document [10]. However, if it is
stored as a molfile with two components in a database this
creates problems, especially when calculating properties.
Representing it as a racemate with no stereochemistry shown
or as a single enantiomer is also arguably incorrect. So, what is
seemingly the same compound is represented in Drugbank
and PubChem as a single enantiomer but in ChEMBL and
DailyMed as a racemate. A second structural class that is not
well described in v2000 molfiles is that of coordination
compounds, such as the drug Cisplatin. Here there is no
method for adequately representing the dative bonds. Again,
the molecule can be drawn on paper but in databases it is
represented in various ways to try and overcome thewww.drugdiscoverytoday.com 19
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representations are shown in (Fig. 1b).
Although v2000 molfiles are still the format of choice for
storing structures in databases, thereby enabling substructure
and similarity searching, when comparing the presence or
absence of compounds across public databases it is most
commonly the Standard InChI (or Standard InChIKey) that
is used [11]. Most of the time this works extremely well and it
has the advantage that the Standard InChI is tautomer inde-
pendent, but again there are currently known limitations. For
example, some types of 1,5 tautomers, such as the structures
shown in Fig. 1c, would not be identified as the same com-
pound from the Standard InChI. Also relative stereochemis-
try can be captured in a non-Standard InChI [12] but as it is
the Standard InChI that is used to determine structure
uniqueness this doesn’t help with database mapping for
compounds, such as the Milnacipran example shown above.
Interestingly the Standard InChI is also unable to distinguish
between Cisplatin and Transplatin as it does not recognise
the cis- and trans-geometric isomerism of the platinum.
Business rules for standardisation
Most database providers have their own set of business rules
that they use for standardising chemical structures. These
tend not to be so strict as those deployed by pharmaceutical
companies in their registration systems, where a key driver is
the ability to prove novelty for intellectual property purposes.
For publicly available databases, basing their business rules
on guidelines such as those produced by the FDA for their
substance registration system [13] is adequate for most pur-
poses. Database providers will, however, have preferences
and rules for whether compounds are ‘merged’ at a parent
level, how nitro groups and sulphoxides are standardised and
whether tautomers are canonicalised and if so, how this is
done. Taking a simple case such as the representation of a
nitro group, whether it is standardised as the pentavalent or
charge separated form does not matter, but what is important
is that it is standardised consistently throughout a database.
Some database providers make their rules and standardisa-
tion software available for people to use online. The Pub-
Chem Standardisation Service is an example of this [a]. This is
the same set of validation and standardisations that they
apply to deposited structures. The process consists of a vali-
dation step where, for example, the structure is checked for
valid atom types, valence checks are performed and function-
al groups such as nitro groups are converted to a consistent
representation. This is followed by a standardisation step in
which converted to a canonical tautomeric form, aromatic
structures are kekulised, placement of stereo bonds are stan-
dardised and all implicit hydrogens are converted to explicit
hydrogens.
The Royal Society of Chemistry (RSC) has also recently
made their Chemical Validation and Standardisation20 www.drugdiscoverytoday.comPlatform (CVSP) available for people to use on their own
compounds [15]. This also applies a series of validation and
standardisations and is based on GGA’s Indigo and OpenEye’s
toolkits as well as some in-house standardisation libraries. In
contrast to the PubChem Standardisation Service, the RSC
have recognised that database providers can have different
requirements for standardisations and CVSP has been written
such that a user can select their own preferences for the set of
standardisation rules to use and apply just those to their
compounds.
Other database providers, such as ChEMBL, have imple-
mented their validation and standardisation process using
pipelining tools such as Pipeline Pilot or Knime. These tools
also allow flexibility such that new components can be added
or adapted as business needs change. The ChEMBL database
providers routinely include a salt stripping process in their
standardisation based on a dictionary of pharmaceutically
relevant salts. This enables bioactivity data, whilst recorded
against the experimental salt, to be grouped at the parent
level.
Software vendors are also aware of the needs of chemoin-
formaticians to be able to standardise large sets of com-
pounds, whether it is for database creation or for
preprocessing prior to analysis. Off the shelf solutions such
as ChemAxon’s standardizer [16] or Biovia’s Cheshire [17] are
also now available. These also have the flexibility for users to
select the appropriate standardisations that meet their busi-
ness needs and then to process molecules and standardise
them in a consistent manner.
Tautomerisation is a complex topic for database providers
and a few years ago was the subject of a whole issue of the
Journal of Computer Aided Molecular Design [18]. In this,
Wendy Warr [19] outlined the various approaches taken by
27 software vendors and database providers to treat tauto-
mers. There is still no consensus on whether tautomers
should be canonicalised and if so how it is done. Currently,
some database providers canonicalise tautomers while others
do not. In general, although databases do show a single
tautomeric representation, ChEBI being a notable exception
[20]. The ‘preferred’ tautomer used in a database matters in
the sense that molecules drawn as different tautomers will
not be recognised as the same structure in substructure or
similarity searches. Also, the physicochemical properties cal-
culated on a compound will generally be different for differ-
ent tautomeric forms.
The ideal situation would be that all database providers
standardise their compounds in the same way as this would
greatly enhance data exchange and integration but this is
probably some way off. The good news is that the Standard
InChI and Standard InChIKey are independent of many of
these structure representations, including tautomers. Thus,
this enables users to use the Standard InChIKey as an identi-
fier for the occurrence of a compound in different databases,
Vol. 14, 2015 Drug Discovery Today: Technologies | From chemistry to biology database curationin most cases, irrespective of its stored structural representa-
tion or tautomeric form.
Matching across databases
For all the reasons discussed above, there will be intended and
unintended differences between the chemical structure re-
presentation of compounds in different databases and this is
something that users of these databases need to be aware of
and accept when using them. Lipinski et al., for example,
highlighted the difficulty in identifying structures and hence
bioactivity data in different databases for the NIH Molecular
Library Probes [21] which are a relatively well known and well
characterised compound set. However, there are now
approaches being taken by some data providers, such as
PubChem, Open PHACTS and ChEMBL, to help link com-
pounds where the structures have been incompletely or
incorrectly represented. One goal of the Open PHACTS proj-
ect is to enable the easy searching and retrieval of different
data types across varied data sources. In the chemistry space
they are developing methods that allow the user to decide
whether they consider different tautomers or different stereo-
isomers for example as ‘the same physical entity’ [1]. The
National Institutes of Health (NIH) in the USA has developed
a Chemical Structure Lookup Service (CSLS) that identifies
which databases a particular structure occurs in. This search
can be done on the basis of different levels of specificity such
as tautomerism, counter ions, isotopes, charges and stereo-
chemistry, and currently searches across 74 million structures
in over 100 databases (http://cactus.nci.nih.gov/cgi-bin/
lookup/search). Using their methodology they were able to
identify the number of unique parent molecules in a large
number of databases and then the number of compounds
that were tautomers of each other [22]. On average they
found that 0.3% of the structures in the individual databases
were tautomers, although this did vary from database to
database. They also showed in an analysis of 103 million
original structure records from about 150 databases that once
the parent structures were generated, and the differences just
due to tautomers removed, only 70.6 million structures
remained. This is a reduction in unique compounds of about
30%.
UniChem [23] is a mapping service developed at EMBL-EBI
based on Standard InChIKeys that can be used to map com-
pounds between databases. Currently, it contains 97 million
structure records, of which 63 million are unique com-
pounds, and it provides compound mappings across 22 dif-
ferent databases. As with the CSLS system, it shows tautomer
independent matches, as defined by the Standard InChIKey,
and has recently been enhanced to enable connectivity map-
ping of compounds between databases (https://www.ebi.ac.
uk/unichem/widesearch/widesearch) [24]. This is achieved
simply by identifying the differences or similarities in the
InChI layers. For example, it will show where there is theracemate of a compound in one database and a specific
enantiomer in another, a salt in one database and the parent
in another or an isotopic difference between compounds in
different databases.
As a way of exemplifying the use of this and showing the
variability of structural forms in databases, the connectivity
mapping obtained using UniChem for Paroxetine and some
of its related forms is shown in Fig. 2. This is particularly
useful as it means that the user can easily identify compounds
across databases that vary only by the individual differences
or combination of differences that they are interested in.
These differences can be stereochemistry, salt forms, isotopic
substitution or charge. The reasons for these discrepancies
can be due to genuine differences, errors in structure drawing
or disparity in business rules, such as storing parent versus salt
forms or use of charges on basic nitrogen for docking studies.
It is worth pointing out that this will not identify tautomeric
differences in structures, as the Standard InChI that is used for
the mapping is tautomer independent.
To highlight the full benefits of a connectivity mapping
approach we have compared the differences in the number of
compounds mapped between all the databases in UniChem,
using connectivity versus exact mapping (Table 2). Unsur-
prisingly, in virtually all cases, the connectivity mapping
results in higher numbers of compound matches between
databases. The difference in some cases is as high as 20%. For
example, it can be seen that matching compounds on the
basis of connectivity results in 67.15% of the DrugBank
compounds matching a compound in ChEMBL, whereas
comparing exact matches it is only 53.58%. In terms of
numbers this is an additional 780 compounds that have
the same connectivity but have different stereochemistry,
charge among others. In the example of SureChEMBL to
ChEMBL, the connectivity mapping results in an extra 3%
of matches, which equates to identification of an extra 1600
compounds in the patent literature for which there is data on
a related compound in ChEMBL. There are several use cases
where these mappings can potentially be very useful to both
users and database providers. Firstly, while different salt
forms will have different InChIs and so not be identified as
‘the same’, from a bioactivity perspective it doesn’t generally
matter what the salt form is and so being able to link these
compounds is useful. An example of the potential of this is for
the marketed drug Sildenafil. The drug is sold as the citrate
salt but in ChEMBL, for example, most of the bioactivity data
has been determined on the parent (22 data points for the
citrate salt versus >1000 on the parent). It is also a tool for
potentially identifying which compounds should be consid-
ered for curation. For example, if database A has no exact
matches to a compound in any other database (or a small
number of matches) but many connectivity matches, this
might suggest there is a stereochemistry error in the structure
in database A. It might also enable users to identify commonwww.drugdiscoverytoday.com 21
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(a)
(b)
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Figure 2. (a) Examples of Paroxetine-like structures in different databases. Paroxetine is the first structure. The Standard InChI for each structure is
shown as is the number of database entries for that particular structure. (b) Database examples of salts and mixtures of compounds where one component
is a connectivity match of Paroxetine.
22 www.drugdiscoverytoday.com
V
o
l.
 1
4
,
 2
0
1
5
 
D
ru
g
 D
isc
o
v
e
ry
 T
o
d
a
y
:
 T
e
c
h
n
o
lo
g
ie
s
 |
 F
ro
m
 c
h
e
m
istry
 to
 b
io
lo
g
y
 d
a
ta
b
a
se
 c
u
ra
tio
n
Table 2. Percentage of exact compound to compound matches between databases determined using Standard InChIKey matches from UniChem. The percentage of
compound connectivity matches (also from UniChem) is shown in brackets. The percentages are calculated as the percent of source ‘X’ (header row) which overlaps
with source ‘Y’ (first column). Full descriptions of the sources are available at https://www.ebi.ac.uk/unichem/ucquery/listSources
chembl drugbank pdb iuphar pubchem_dotf kegg_ligand chebi nih_ncc zinc emolecules ibm
chembl 100 (100) 53.58 (67.15) 41.26 (50.18) 65.60 (81.90) 62.64 (77.15) 42.27 (50.86) 29.14 (41.98) 91.09 (98.74) 1.3 (3.11) 6.95 (7.48) 2.78 (3.33)
drugbank 0.25 (0.34) 100 (100) 23.41 (31.38) 14.01 (20.57) 9.21 (17.57) 9.13 (13.79) 7.22 (13.07) 35.60 (72.98) 0.01 (0.02) 0.04 (0.06) 0.08 (0.12)
pdb 0.50 (0.65) 60.92 (79.16) 100 (100) 9.12 (14.66) 7.93 (13.30) 11.69 (15.71) 10.28 (16.21) 15.43 (35.09) 0.01 (0.03) 0.07 (0.09) 0.14 (0.18)
iuphar 0.08 (0.11) 3.61 (5.20) 0.9 (1.47) 100 (100) 3.29 (6.72) 2.10 (3.21) 1.19 (2.39) 7.23 (21.44) 0.00 (0.01) 0.01 (0.02) 0.03 (0.03)
pubchem_dotf 0.26 (0.36) 8.19 (15.89) 2.71 (4.77) 11.38 (24.06) 100 (100) 3.79 (6.96) 3.25 (6.26) 39.49 (57.10) 0.00 (0.02) 0.03 (0.05) 0.06 (0.11)
kegg_ligand 0.44 (0.54) 20.16 (28.48) 9.93 (12.85) 18.05 (26.22) 9.42 (15.89) 100 (100) 22.05 (34.66) 32.82 (63.92) 0.02 (0.04) 0.10 (0.13) 0.19 (0.24)
chebi 0.59 (0.62) 30.99 (37.81) 16.96 (18.59) 19.88 (27.42) 15.69 (20.02) 42.85 (48.58) 100 (100) 49.37 (71.30) 0.02 (0.04) 0.14 (0.15) 0.27 (0.29)
nih_ncc 0.05 (0.06) 4.03 (8.40) 0.67 (1.60) 3.18 (9.78) 5.03 (7.27) 1.68 (3.57) 1.30 (2.84) 100 (100) 0.00 (0.00) 0.01 (0.01) 0.01 (0.02)
zinc 20.85 (37.04) 21.59 (45.75) 16.13 (27.42) 16.34 (54.28) 16.02 (41.43) 24.37 (48.33) 18.47 (35.64) 31.43 (91.36) 100 (100) 54.79 (90.29) 3.31 (5.43)
emolecules 26.56 (30.71) 34.49 (49.76) 21.26 (29.60) 39.35 (63.17) 31.66 (42.23) 37.21 (49.48) 26.68 (42.04) 84.28 (96.93) 13.04 (31.09) 100 (100) 4.22 (4.80)
ibm 5.08 (6.58) 32.93 (44.84) 20.90 (27.23) 38.67 (52.12) 25.89 (49.14) 33.53 (44.55) 24.35 (39.30) 43.53 (83.84) 0.38 (0.90) 2.02 (2.31) 100 (100)
atlas 0.04 (0.05) 3.84 (5.32) 1.37 (1.94) 4.10 (6.22) 2.14 (3.60) 2.42 (3.22) 1.71 (2.91) 10.70 (20.75) 0.00 (0.00) 0.01 (0.01) 0.01 (0.02)
patents 2.35 (3.08) 29.39 (38.94) 14.10 (19.2) 29.68 (41.46) 21.41 (41.89) 27.39 (37.83) 18.87 (31.1) 45.06 (84.81) 0.12 (0.30) 0.66 (0.78) 13.12 (13.56)
fdasrs 1.05 (1.07) 26.84 (33.96) 13.47 (15.08) 24.11 (36.50) 40.63 (48.20) 32.85 (38.26) 20.27 (27.28) 58.27 (79.24) 0.04 (0.09) 0.28 (0.28) 0.49 (0.60)
surechembl 17.59 (20.83) 50.26 (70.61) 36.62 (50.80) 60.58 (75.61) 66.50 (81.71) 45.14 (61.77) 28.31 (48.1) 79.13 (94.84) 0.89 (2.02) 4.41 (4.78) 62.67 (68.35)
pharmgkb 0.05 (0.06) 9.65 (11.62) 1.26 (2.00) 7.53 (10.92) 3.56 (7.09) 3.36 (4.43) 2.18 (3.70) 23.22 (45.26) 0.00 (0.00) 0.01 (0.02) 0.02 (0.03)
hmdb 0.32 (0.50) 27.44 (32.99) 7.74 (10.96) 15.66 (23.61) 9.28 (17.63) 21.49 (31.56) 13.90 (26.89) 36.99 (74.09) 0.01 (0.04) 0.10 (0.13) 0.20 (0.27)
selleck 0.12 (0.14) 7.26 (13.63) 2.38 (3.97) 5.08 (12.76) 12.06 (15.66) 3.17 (5.70) 2.67 (5.15) 42.28 (58.63) 0.00 (0.01) 0.03 (0.03) 0.02 (0.04)
pubchem_tpharma 26.68 (32.04) 55.71 (72.99) 45.17 (56.8) 67.93 (88.76) 76.26 (90.56) 55.26 (69.18) 43.98 (64.46) 81.64 (96.51) 0.52 (1.16) 2.46 (2.75) 6.85 (8.48)
pubchem 94.66 (96.73) 94.66 (97.4) 83.09 (89.66) 93.63 (99.17) 96.33 (98.49) 96.27 (98.43) 93.85 (97.31) 95.13 (97.63) 41.11 (57.83) 93.63 (95.03) 79.82 (82.32)
mcule 24.16 (27.89) 16.68 (22.66) 11.11 (14.29) 12.97 (17.26) 8.04 (13.53) 14.94 (19.74) 10.55 (16.76) 42.00 (62.11) 14.73 (31.55) 76.06 (81.94) 2.22 (2.31)
nmrshiftdb2 0.08 (0.11) 1.81 (3.35) 1.48 (2.23) 1.35 (3.11) 0.21 (1.40) 2.98 (3.95) 2.25 (3.93) 0.97 (4.6) 0.00 (0.01) 0.03 (0.03) 0.07 (0.07)
atlas patents fdasrs surechembl pharmgkb hmdb selleck pubchem_tpharma pubchem mcule nmrshiftdb2
chembl 82.84 (91.11) 7.82 (9.45) 42.05 (50.13) 1.91 (2.39) 86.94 (95.63) 10.68 (15.5) 82.59 (93.46) 9.35 (11.25) 2.6 (3.07) 5.45 (6.42) 27.37 (35.23)
drugbank 36.09 (50.84) 0.46 (0.61) 5.05 (8.11) 0.03 (0.04) 75.49 (90.39) 4.32 (5.21) 24.39 (45.92) 0.09 (0.13) 0.01 (0.02) 0.02 (0.03) 2.81 (5.32)
pdb 33.43 (46.70) 0.57 (0.76) 6.60 (9.08) 0.05 (0.08) 25.73 (39.27) 3.17 (4.37) 20.84 (33.71) 0.19 (0.26) 0.03 (0.04) 0.03 (0.04) 5.99 (8.93)
iuphar 9.91 (15.00) 0.12 (0.16) 1.17 (2.20) 0.01 (0.01) 15.14 (21.44) 0.63 (0.94) 4.39 (10.85) 0.03 (0.04) 0.00 (0.00) 0.00 (0.01) 0.54 (1.25)
pubchem_dotf 17.89 (31.08) 0.30 (0.59) 6.79 (10.4) 0.03 (0.04) 24.75 (49.87) 1.30 (2.52) 36.03 (47.67) 0.11 (0.15) 0.01 (0.01) 0.01 (0.01) 0.29 (2.01)
kegg_ligand 50.14 (63.39) 0.95 (1.22) 13.64 (18.84) 0.05 (0.07) 58.00 (71.07) 7.47 (10.28) 23.54 (39.57) 0.20 (0.26) 0.03 (0.03) 0.03 (0.05) 10.22 (12.92)
chebi 68.93 (80.39) 1.27 (1.41) 16.37 (18.83) 0.06 (0.08) 73.15 (83.16) 9.39 (12.27) 38.51 (50.18) 0.31 (0.33) 0.05 (0.05) 0.05 (0.06) 14.99 (18.03)
nih_ncc 11.39 (22.81) 0.08 (0.15) 1.24 (2.18) 0.00 (0.01) 20.56 (40.52) 0.66 (1.35) 16.08 (22.73) 0.02 (0.02) 0.00 (0.00) 0.01 (0.01) 0.17 (0.84)
zinc 34.91 (72.74) 6.32 (10.94) 26.85 (48.34) 1.55 (2.78) 34.48 (83.29) 6.76 (15.34) 37.24 (80.61) 2.93 (4.86) 18.12 (21.92) 53.31 (86.67) 24.1 (35.25)
emolecules 75.14 (89.73) 8.45 (9.78) 42.85 (52.78) 1.83 (2.26) 76.35 (94.63) 12.66 (17.06) 81.16 (88.98) 3.30 (3.98) 9.83 (12.4) 65.52 (77.51) 35.45 (40.06)
ibm 51.92 (67.68) 79.78 (82.26) 35.72 (55.33) 12.46 (15.54) 70.93 (81.42) 12.10 (16.43) 28.51 (53.50) 4.39 (5.9) 4.01 (5.17) 0.91 (1.05) 39.71 (44.92)
atlas 100 (100) 0.07 (0.10) 1.18 (1.79) 0.00 (0.01) 18.47 (22.31) 0.67 (0.89) 7.67 (12.63) 0.01 (0.02) 0.00 (0.00) 0.00 (0.01) 1.03 (1.78)
patents 43.04 (58.19) 100 (100) 27.53 (43.31) 2.26 (2.80) 71.30 (79.3) 9.26 (12.48) 29.41 (53.72) 1.66 (2.22) 0.80 (1.00) 0.31 (0.36) 18.98 (22.69)
fdasrs 58.72 (71.51) 2.29 (2.85) 100 (100) 0.14 (0.17) 65.51 (81.29) 9.47 (12.12) 63.54 (75.20) 0.57 (0.57) 0.06 (0.06) 0.09 (0.11) 20.06 (24.39)
surechembl 55.17 (84.22) 68.97 (74.61) 51.11 (70.68) 100 (100) 72.90 (92.39) 13.33 (19.32) 80.37 (94.70) 31.42 (36.66) 19.23 (21.72) 2.29 (2.7) 18.74 (41.74)
pharmgkb 22.18 (27.41) 0.14 (0.16) 1.57 (2.50) 0.00 (0.01) 100 (100) 1.52 (1.83) 10.89 (21.16) 0.02 (0.02) 0.00 (0.00) 0.01 (0.01) 0.73 (1.53)
hmdb 40.23 (54.05) 0.92 (1.24) 11.31 (18.33) 0.04 (0.07) 75.36 (90.14) 100 (100) 24.44 (46.22) 0.19 (0.31) 0.04 (0.06) 0.03 (0.05) 9.49 (13.22)
selleck 21.44 (35.83) 0.14 (0.25) 3.56 (5.33) 0.01 (0.02) 25.36 (48.87) 1.14 (2.17) 100 (100) 0.04 (0.05) 0.00 (0.00) 0.01 (0.01) 0.54 (2.09)
pubchem_tpharma 80.32 (90.96) 15.71 (19.34) 65.63 (75.92) 9.75 (11.99) 86.33 (97.88) 17.68 (26.89) 88.09 (97.08) 100 (100) 7.46 (8.86) 1.08 (1.41) 56.39 (70.21)
pubchem 91.42 (97.70) 96.6 (96.91) 92.61 (95.28) 76.13 (78.58) 96.92 (99.25) 43.3 (53.74) 95.02 (98.64) 95.16 (97.9) 100 (100) 94.19 (97.89) 88.98 (98.75)
mcule 37.57 (48.54) 4.50 (4.74) 15.26 (22.13) 1.10 (1.35) 45.56 (58.10) 5.12 (6.33) 26.29 (40.41) 1.68 (2.15) 11.48 (13.51) 100 (100) 18.44 (20.83)
nmrshiftdb2 6.21 (10.71) 0.19 (0.22) 2.43 (3.67) 0.01 (0.02) 3.69 (7.48) 0.96 (1.32) 1.16 (4.43) 0.06 (0.08) 0.01 (0.01) 0.01 (0.02) 100 (100)
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Drug Discovery Today: Technologies | From chemistry to biology database curation Vol. 14, 2015compounds where the business rules for compound standar-
disation are different between databases. Obviously it has to
be left up to the user to make their own assessment as to
whether these differences are important in the context of
their own research interests.
Conclusions
The number of chemical databases in the public domain and
the number of chemical structures within them is now large
and likely to continue increasing in future years, particularly
as automated extraction methods such as image to structure
software becomes more reliable. Is it now time to accept that
however diligent database providers are, there will always be
differences in structure representations and indeed some
errors in the structures that cannot be fixed with a realistic
level of resource? Should we therefore turn our attention to
encouraging the use and development of tools that enable
the mapping together of related compounds rather than
concentrate our efforts on ever more curation?
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